Alloantibodies and RBC autoantibodies detected in thalassemia patients according to the extent of RBC phenotype of the transfused blood
| . | Group I (n = 29) . | Group II (n = 26) . | Group III (n = 35; 9 + 26) . | Total no.in all patients . | Total no.in Asian patients . |
|---|---|---|---|---|---|
| Alloantibodies | |||||
| Anti-K* | 2 | 4 | — | 6 | 4 |
| Anti-c* | 1 | 1 | — | 2 | 1 |
| Anti-E* | 1 | 3 | — | 4 | 1 |
| Anti-JKb* | — | — | 1 | 1 | 1 |
| Anti-Lea | — | 1 | — | 1 | 1 |
| Anti-Kp-a* | — | 1 | — | 1 | 1 |
| Anti-M | — | 1 | — | 1 | 1 |
| Anti-i | 2 | — | — | 2 | 2 |
| HTLA | — | 1 | — | 1 | 1 |
| Total | 6 | 12 | 1 | 19 | 13 |
| Total clinically significant | 4 | 9 | 1 | 14 | 8 |
| Total autoantibodies | 5 | 9 | 2 | 16 | 14 |
| . | Group I (n = 29) . | Group II (n = 26) . | Group III (n = 35; 9 + 26) . | Total no.in all patients . | Total no.in Asian patients . |
|---|---|---|---|---|---|
| Alloantibodies | |||||
| Anti-K* | 2 | 4 | — | 6 | 4 |
| Anti-c* | 1 | 1 | — | 2 | 1 |
| Anti-E* | 1 | 3 | — | 4 | 1 |
| Anti-JKb* | — | — | 1 | 1 | 1 |
| Anti-Lea | — | 1 | — | 1 | 1 |
| Anti-Kp-a* | — | 1 | — | 1 | 1 |
| Anti-M | — | 1 | — | 1 | 1 |
| Anti-i | 2 | — | — | 2 | 2 |
| HTLA | — | 1 | — | 1 | 1 |
| Total | 6 | 12 | 1 | 19 | 13 |
| Total clinically significant | 4 | 9 | 1 | 14 | 8 |
| Total autoantibodies | 5 | 9 | 2 | 16 | 14 |
HTLA indicates high titer, low avidity.
Indicates clinically significant.